HEALTH PLANS
UNIVERSITY OF UTAH

PRIOR AUTHORIZATION REQUEST FORM
PULMONARY HYPERTENSION (PH) MEDICATIONS

Adempas®, Flolan®, Letairis®, Orenitram®, Remodulin®, Revatio®, Tyvaso®, Uptravi®, Veletri®, Ventavis®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

- For **Medical Pharmacy** please fax requests to 801-213-1547.
- For **Retail Pharmacy** requests please fax requests to: Commercial Groups, Individual & Family Plans please fax request to 888-509-8142. For Healthy U Medicaid, University of Utah Health Employees please fax request to 844-316-3655

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans: 855-869-4769, Commercial Groups: 855-859-4892, MHC: 855-885-7695, Advantage U Part B: 888-605-0858

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: ☐ Adempas® (riociguat), ☐ ambrisentan, ☐ epoprostenol, ☐ Orenitram® (treprostinil), ☐ sildenafil oral suspension, ☐ sildenafil oral tablets, ☐ tadalafil, ☐ Uptravi® (selexipag)
Non-preferred: ☐ bosentan, ☐ Opsumit® (macitentan), ☐ Tyvaso® (treprostinil), ☐ Ventavis® (iloprost)

**bosentan and Opsumit® require trial and failure of ambrisentan*
**tadalafil require trial and failure of sildenafil tablets unless clinical documentation demonstrates medical necessity.*

Dosing/Frequency:_____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of Pulmonary Arterial Hypertension (PAH)?	☐	☐	
2. Is the member classified as WHO (World health Organization) Group 1 pulmonary arterial hypertension? If not, please provide the WHO group classification.	☐	☐	**Please provide documentation**
3. Is the requesting provider a cardiologist or pulmonologist specializing in pulmonary hypertension?	☐	☐	
4. Has the member shown to be at least 75% compliant with provider visits in the past 12 months?	☐	☐	**Please provide documentation**
5. Has the member demonstrated at least 80% compliance with pulmonary hypertension medications?	☐	☐	**Please provide documentation**

6. If the member has a positive vasoreactivity test, have they had a trial and failure of oral calcium channel blocker therapy with dihydropyridine or diltiazem?	☐	☐	**Please provide documentation**
7. Has the patient undergone a urine drug screening?	☐	☐	**Please provide documentation**
8. Is the patient currently smoking tobacco?	☐	☐	
9. Has the patient performed a baseline 6-minute walk test?	☐	☐	**Please provide documentation**
PHOSPHODIESTERASE-5 INHIBITORS: SILDENAFIL, TADALAFIL			
1. If the request is for sildenafil oral suspension, is the member less than 8 years of age or unable to swallow tablets?	☐	☐	**Please provide documentation**
2. If the request is for tadalafil tablets, has the member had a 3-month trial and failure of sildenafil with at least 1 month at the maximum tolerated dose?	☐	☐	**Please provide documentation**
ENDOTHELIN RECEPTOR ANTAGONISTS: AMBRISENTAN, BOSENTAN, OPSUMIT®			
1. If the request is for ambrisentan, will it be used in combination with a phosphodiesterase inhibitor?	☐	☐	**Please provide documentation**
2. If the request is for bosentan, has ambrisentan been trialed and failed?	☐	☐	**Please provide documentation**
3. If the request is for Opsumit®, will it be used in combination with a phosphodiesterase inhibitor AND has ambrisentan been trialed and failed?	☐	☐	**Please provide documentation**
PROSTACYCLIN PATHWAY AGONISTS: ORENITRAM®, TREPROSTINIL IV, TREPROSTINIL SQ, TYVASO® UPTRAVI®, VENTAVIS®			
1. Do any of the following apply: • Has the member tried and failed combination treatment with a PDE5 inhibitor (such as sildenafil or tadalafil) with ambrisentan? • Is the member in WHO functional class III with clinical documentation showing rapid progression or have other markers of poor clinical prognosis? • Is the member in WHO functional class IV?	☐	☐	**Please provide documentation**
2. For Tyvaso® and Ventavis® only, has the member had a trial and failure to treprostinil IV or SQ?	☐	☐	**Please provide documentation**
GUANYLATE CYCLASE STIMULATOR: ADEMPAS®			
1. Is the member in WHO functional class II, III, or IV?	☐	☐	**Please provide documentation**
2. If the member has a clinical diagnosis of WHO group 1, have they tried and failed combination therapy with a PDE5 inhibitor (such as sildenafil or tadalafil) with ambrisentan?	☐	☐	**Please provide documentation**
3. Does the member have a clinical diagnosis of WHO Group 4 PAH after surgical treatment OR have confirmed inoperable chronic thromboembolic pulmonary hypertension?	☐	☐	**Please provide documentation**
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	☐	☐	
2. Does documentation show disease improvement or stabilization (e.g. improvement in 6 minute walk test, functional class, pulmonary arterial pressure, cardiac index, etc.)?	☐	☐	**Please provide documentation**

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.
Additional information:
Physician's Signature:

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 063
Origination Date: 05/02/2018
Reviewed/Revised Date: 08/19/2020
Next Review Date: 08/19/2021
Current Effective Date: 09/01/2020